

Supplementary Table 1. SNOMED terms for the SpA variable

| Concept id | SNOMED term- Spanish search |
|--------------------------|--|
| Spondyloarthritis | |
| 201575009 | artropatía reactiva de primera articulación metatarsofálgica |
| 201567003 | artropatía reactiva de la cadera |
| 422565003 | poliartritis posinfecciosa |
| 201563004 | artropatía reactiva de la muñeca |
| 201481004 | artropatía reactiva de transmisión sexual, de múltiples localizaciones |
| 239804002 | artritis psoriásica juvenil sin psoriasis |
| 2194 | Espondiloartritis periférica |
| 201570004 | artropatía reactiva de la articulación tibioperonea |
| 239810002 | espondilitis anquilosante con compromiso orgánico/sistémico |
| 239785008 | enfermedad de Reiter posdisentérica |
| 56528004 | artropatía posdisentérica |
| 2195 | Espondiloartritis axial no radiográfica |
| 201805000 | artritis juvenil en la enfermedad de Crohn |
| 81077008 | artritis reumática aguda |
| 201807008 | artritis juvenil en la colitis ulcerosa |
| 201566007 | artropatía reactiva de articulación interfalángica distal de dedo de la mano |
| 239783001 | artritis posinfecciosa |
| 239808004 | síndrome de Reiter juvenil |
| 201474006 | artropatía reactiva de región de hombro adquirida por vía sexual |
| 201477004 | artropatía reactiva de transmisión sexual, de la mano |
| 240428000 | artritis posmeningocócica |
| 201497009 | artropatía reactiva posdisentérica de región de hombro |
| 201738001 | artropatía posinfecciosa en la sífilis |
| 239806000 | espondiloartropatía juvenil |
| 201500003 | artropatía reactiva posdisentérica, de la mano |
| 2154 | Espondilitis indiferenciada periférica |
| 239811003 | espondilitis anquilosante con compromiso multisistémico |
| 201559006 | artropatía reactiva de la articulación esternoclavicular |
| 423515003 | artritis posinfecciosa de articulación del pie |
| 201558003 | artropatía reactiva de hombro |
| 201561002 | artropatía reactiva del codo |
| 123949001 | artritis reactiva posestreptocócica |
| 19514005 | artritis mutilante |
| 429422002 | artritis reumática de articulación temporomandibular |
| 201501004 | artropatía reactiva posdisentérica, de región pélvica y muslo |
| 2148 | Artritis asociada a EIIC |
| 201504007 | artropatía reactiva posdisentérica, de múltiples localizaciones |
| 201573002 | artropatía reactiva de la articulación astragalonavicular |
| 410482007 | iritis en la artritis psoriásica |
| 67224007 | enfermedad de Reiter |

| | |
|-----------|--|
| 201480003 | artropatía reactiva de transmisión sexual, del tobillo y el pie |
| 239813000 | dactilitis psoriásica |
| 239812005 | artritis psoriásica con compromiso de la articulación interfalángica distal |
| 201569000 | artropatía reactiva de la rodilla |
| 201576005 | artropatía reactiva de la quinta articulación metatarsofalángica |
| 239805001 | espondilitis anquilosante juvenil |
| 239787000 | artritis reactiva posttuberculosa |
| 201562009 | artropatía reactiva de la articulación radiocubital distal |
| 200956002 | artritis psoriásica con compromiso vertebral |
| 415141001 | infección genitourinaria consecutiva a enfermedad de Reiter |
| 9631008 | espondilitis anquilosante |
| 239802003 | artritis psoriásica juvenil |
| 423310007 | poliartritis posinfecciosa de articulación de la mano |
| 239803008 | artritis psoriásica juvenil con psoriasis |
| 201564005 | artropatía reactiva de la articulación metacarpofalángica |
| 239809007 | artritis juvenil en la enfermedad intestinal inflamatoria |
| 2149 | Espondiloartritis axial y periférica |
| 129564003 | espondiloartritis anquilosante y lesiones oculares |
| 14175009 | fiebre reumática articular |
| 2153 | Espondilitis indiferenciada axial |
| 162930007 | al examen: deformidad torácica de la espondilitis anquilosante |
| 201572007 | artropatía reactiva de la articulación subastragalina |
| 201571000 | artropatía reactiva del tobillo |
| 2150 | Espondiloartropatía HLA B 27 positivo |
| 201503001 | artropatía reactiva posdisentérica, del tobillo y el pie |
| 267883008 | artritis reactiva postinfección genitourinaria |
| 58769002 | artritis reumática subaguda |
| 201565006 | artropatía reactiva de articulación interfalángica proximal de dedo de la mano |
| 201577001 | artropatía reactiva de articulación interfalángica de dedo del pie |
| 201568008 | artropatía reactiva de la articulación sacroilíaca |
| 2151 | Espondiloartropatía HLA B 27 negativo |
| 201560001 | artropatía reactiva de la articulación acromioclavicular |
| 2193 | Espondiloartritis axial |
| 9350004 | artritis enteropática |
| 201478009 | artropatía reactiva de transmisión sexual, de la región pélvica y del muslo |
| 2152 | Espondiloartropatía indiferenciada |
| 33339001 | psoriasis con artropatía |

Supplementary Table 2. Analysis stratified by time-windows

| Variable | Period 1* | Period 2** | Z-statistic |
|---|----------------|----------------|-------------|
| Total number of patients in the hospital | 422,100 | 473,906 | |
| Total number of SpA patients | 2,725 | 2,988 | 0.89 |
| Demographics and toxic habits | | | |
| Sex (male) | 1,281 (47.01%) | 1,309 (43.81%) | 2.43 |
| Type of involvement | | | |
| Peripheral Spondyloarthritis* | 881 (32.33%) | 941 (31.49%) | 0.68 |
| Axial Spondyloarthritis | 653 (23.96%) | 694 (23.23%) | 0.66 |
| Axial and Peripheral Spondyloarthritis | 56 (2.06%) | 44 (1.47%) | 1.68 |
| Extra-musculoskeletal manifestations | | | |
| Uveitis | 598 (21.94%) | 786 (26.31%) | -3.84 |
| Inflammatory bowel disease | 281 (10.31%) | 326 (10.91%) | -0.73 |
| Psoriasis | 818 (30.02%) | 958 (32.06%) | -1.67 |
| Peripheral manifestations | | | |
| Enthesitis | 548 (20.11%) | 663 (22.19%) | -1.92 |
| Dactylitis | 207 (7.60%) | 227 (7.60%) | -0.001 |
| Cardiovascular risk factors | | | |
| Active smoker | 353 (12.95%) | 390 (13.05%) | -0.11 |
| High blood pressure | 595 (21.83%) | 616 (22.62%) | 1.13 |
| Diabetes Mellitus | 308 (11.30%) | 309 (11.34%) | 1.17 |
| Dyslipidemia | 471 (17.28%) | 523 (19.19%) | -0.22 |
| Treatment | | | |
| Methotrexate | 786 (28.84%) | 861 (28.82%) | 0.02 |
| Sulfasalazine | 403 (14.79%) | 438 (14.66%) | 0.14 |
| Adalimumab | 295 (10.83%) | 359 (12.02%) | -1.41 |
| Infliximab | 179 (6.57%) | 190 (6.36%) | 0.32 |
| Etanercept | 204 (7.49%) | 207 (6.93%) | 0.82 |

*From January 1st 2020 to April 30th 2021; ** From May 1st 2021 to 21st August 2022

Supplementary Text 1

Clinical NLP processing

Savana Manager contains a subset of functionalities of EHRead® technology mainly consisting of a layer of named-entity recognition including named-entity disambiguation plus baseline ML models covering for example negation and temporality detection.

The SpA related variables were detected in the free text using a named-entity recognition approach. This initial step identifies clinical entities within the text, distinguishing them from non-clinical content. Once identified, entities are classified into distinct categories. As additional layers, negation, temporality and section detection were applied. Our general models are trained using standard terminologies such as SNOMED-CT or ATC and meticulously improved through clinician annotations to capture the most relevant expressions for each variable that is not available in the standard version of the terminologies. Therefore, common typos and medical abbreviations are captured, significantly improving their capability to accurately interpret the diverse and often inconsistent terminology found within EHR data.

Negation and speculation recognition model combines rule-based methods for detecting common negation triggers with neural networks capable of handling complex negation structures (1), which has been trained on real Spanish EHRs and evaluated against a rich set of reference standards. This model classifies each clinical entity as being affirmative or non-affirmative based on its lexical and semantic context.

The temporality detection is carried out by a NLP module that consists of various layers that work in combination to assign dates to clinical entities. The first layer is a named-entity detection engine responsible for the detection of any mentioning of dates in the free text of EHRs. Subsequently, a relationship model based on a Bi-LSTM (2) decides if a detected date is related to a detected clinical entity. In addition, a normalization layer takes care of converting different date formats as written in the EHRs' free text into a normalized representation.

As for section detection, the model categorizes sentences within the EHR text into predefined sections (e.g., patient history, current conditions), allowing for a better interpretation of the data.

The last step of the NLP processing, the post-processing step, carries out several quality control operations and combines the output from the different NLP modules into a final database.

- 1- Tay Y, Dehghani M, Gupta J, Bahri D, Aribandi V, Qin Z, et al. Are Pre-trained Convolutions Better than Pre-trained Transformers? [Internet]. arXiv; 2022 [cited 2022 Aug 16]. Available from: <http://arxiv.org/abs/2105.03322>
- 2- Schuster, M. and Paliwal, K.K. (1997) Bidirectional Recurrent Neural 1- Networks. IEEE Transactions on Signal Processing, 45, 2673-2681.2-<https://doi.org/10.1109/78.650093>

Supplementary text 2

Before the data could leave the Hospital Universitario La Paz to Savana's servers via a secure route, an important procedure needed to be executed beforehand during which personal health information was pseudonymized (protected by a pseudonymization step). The pseudonymization process consisted of utilizing a hashing tool for pseudonymization of identifiers to transform identifiers into a set of characters, including patient and episode identifiers, and it was conducted at the Hospital Universitario La Paz. Medsavana supplied the hospital with the necessary tools and support for pseudonymizing the information contained within the EHRs, with Medsavana taking on the role of data processing for this purpose at the hospital.

Given that the hospital performed the pseudonymization of this data before sending it to MedSavana, any supplementary information that could potentially de-anonymize the data and thus reveal patient identities was always kept separated, with MedSavana having no access to it. Following the conclusion of this initial pseudonymization stage, the database was then forwarded to MedSavana's systems.

Moreover, the process focused on the extraction and analysis of clinical variables, and free text from medical records is excluded from the platform, minimizing privacy and confidentiality risks.